dothelium, and finally PMN-mediated injury of the myocardial cells.8-10 The PMN-mediated injury that occurs following myocardial ischemia-reperfusion is characterized by myocardial stunning as well as myocardial cell necrosis. Early studies have demonstrated that treatment strategies aimed at the mechanical removal11'12 or inhibition of PMN activation13-15 have proven successful in ameliorating reperfusion-mediated injury in a number of animal models. Recent experimental evidence suggests that PMN-mediated myocardial reperfusion injury can be most effectively limited by the inhibition of the complement cascade or by inhibition of PMN adhesion to the coronary endothelium.
The complement system plays a pivotal role in the recruitment and activation of PMNs within the ischemic-reperfused myocardium. 16 Maroko et al'7 originally observed significant reductions in myocardial damage following coronary occlusion if the complement system had been inactivated with cobra venom factor. More recently, Rossen 
Electron Paramagnetic Resonance Measurements
In additional experiments, the effect of MAb R15.7 on the production of oxygen-derived free radicals by human PMNs was determined using EPR spectroscopy. Human PMNs were isolated as described previously and stored at 4°C until use. Aliquots of the PMNs (1.Ox 106)
were activated with either activated zymosan, leukotriene B4 (100 nmol/L), or phorbol myristate acetate (PMA, 10 ng/mL) in the presence or absence of MAb R15.7 (20 ,ug/mL) and placed in a quartz EPR flat cell (Wilmad Glass Co). EPR spectra were recorded at room temperature with a Bruker-IBM ER 300 spectrometer operating at X-band using a TM110 cavity, a modulation frequency of 100 kHz, a modulation amplitude of 0.5 G, a microwave power of 20 mW, and a microwave frequency of 9.77 GHz. Each spectral acquisition file was the sum of 10 1-minute scans. The digital Bruker spectral data were transferred to an Intel 486-based personal computer for analysis. Software capable of isotropic spectral simulation, developed in this laboratory, was used for component analysis of experimental spectra as described previously.28 Spectral simulations consisting of linear combinations of the component signals were performed to match the observed spectra. From the weighted intensities of each component in these simulations, the relative amount of each component signal was determined. The total radical concentration was then determined from the ratio of the double integral of the observed spectra to the known concentration of 2,2,6,6-tetramethylpiperidinoxy free radical in aqueous solution as previously described. 28, 29 Cardiac Myeloperoxidase Determination Myeloperoxidase activity, an enzyme virtually exclusive for PMNs, was determined in the rat hearts according to the method of Bradley et a130 as modified by Mullane et aP3' and used as an index of PMN accumulation in the heart. After the 45-minute reperfusion period, the hearts were removed from the perfusion apparatus and rapidly frozen in liquid nitrogen. The hearts were stored at -80°C until homogenization. The myocardial tissue was homogenized in 0.5% hexadecyltrimethyl ammonium bromide (Sigma Chemical) and dissolved in 50 mmol/L K phosphate buffer at pH 6.0 using a Polytron (PCU-2) homogenizer (Kinemutica GmbH, Lucerne, Switzerland) for 15 seconds twice at 7000 rpm. Homogenates were centrifuged for 20 minutes at 12 000g and 2°C. The supernatants were decanted and added to 0.167 mg/mL O-dianisodine dihydrochloride (Sigma Chemical) and 0.005% H202 in 50 mmol/L phosphate buffer at pH 6.0. The change in absorbance was measured spectrophotometrically at 460 nm. One unit of myeloperoxidase activity is defined as the quantity of enzyme degrading 1 ,mol peroxide/ min at 25°C. The measured myeloperoxidase activity of 106 PMNs was 0.60 units.
Experimental Protocol
The experimental protocol for the isolated heart perfusion studies is depicted in Fig 2. After a 10-to 15-minute equilibration period, baseline left ventricular developed pressure, left ventricular end-diastolic pressure, and coronary flow were measured. At the onset of ischemia, the balloon was deflated. The intraventricular balloon volume was then reinflated with the previous volume immediately after the onset of reflow. The hearts were reperfused for the first 5 minutes with human PMNs (50 million) and rat plasma (5%) along with standard Krebs buffer, with or without MAb R15.7
(20 1tg/mL). After this, perfusion was continued with Krebs buffer alone for an additional 40 minutes, during which serial measurements of coronary flow and developed pressure were performed every 5 minutes. One or more sidearm ports were placed just above the aortic cannula, allowing administration of cells, plasma, or both (Fig 1) . As 20 ,ug/mL of MAb R15.7 was sufficient to completely inhibit complement-mediated PMN free radical generation, we conducted additional experiments measuring free radical generation using electron paramagnetic resonance spectroscopy. The effects of R15.7 on activated PMNs were studied in aliquots of freshly isolated human PMNs. Human PMNs were initially stimulated with zymosan activated plasma, 5% volume activated with 200 ,ug/mL zymosan, in the presence of a 50-mmol/L concentration of the spin-trap agent DMPO. A profound burst of oxygen free radical generation was observed with a prominent DMPO-OH 1: 2:2:1 quartet signal whose magnitude peaked at 60 to 90 minutes after activation (Fig 4A) . In the presence of 100 units/mL of recombinant human superoxide dismutase (HSOD), this signal was completely quenched, demonstrating that the observed DMPO-OH adduct was derived from superoxide. Pretreatment with R15.7 (20 ,ug/mL) almost completely abolished free radical generation by PMNs stimulated with activated zymosan (Fig 4B) . In contrast, R15.7 had little or no effect on PMN free radical generation by PMNs (Fig 7) was very similar in the two groups of hearts. After ischemia and reperfusion with HNRP for 5 Cardiac myeloperoxidase activity. At the end of reperfusion (45 minutes), cardiac myeloperoxidase activity was 0.3±0.05 units/100 mg of tissue in the HNRP group compared with 0.02±0.01 units/100 mg tissue in the HNRP+MAb R15.7 group (P<.001) (Fig 9) . This finding is consistent with markedly attenuated PMN accumulation following global ischemia and reperfusion in hearts receiving MAb R15.7. The average total myeloperoxidase activity per heart was 4.5 units in the HNRP group, indicating that approximately 7.5x 106 PMNs, which corresponds to 15% of the infused PMNs, remained in the heart after 45 minutes of reflow. In the HNRP+MAb R15.7 group, the average total myeloperoxidase activity per heart was 0.3 units, corresponding to 0.5 x106 PMNs, or 1% of those infused. Experiments With a PMN-Binding Nonblocking Antibody
To prove that the effect of MAb R15.7 was specifically due to the blocking of CD-18, additional experiments were performed in which hearts were reperfused with a PMN-binding antibody that has been previously shown to be ineffective in blocking adhesion via CD-18. For these experiments, MAb R3.1 was used, which is a specific antibody to the a-subunit of LFA-1, CD-11a. Hearts were subjected to the same protocol of 20 minutes of ischemia and 45 minutes of reperfusion that was used in the MAb R15.7 experiments with identical antibody concentration and infusion duration. Despite this antibody administration, marked injury was observed with severe impairment of contractile function and coronary flow (Table) . For all physiological parameters studied, the recovery with MAb R15.7 was significantly higher than that with MAb R3.1 with P<.01. The differences were striking and almost as marked as those seen with simple vehicle infusion. Tissue myeloperoxidase activity was measured after 45 minutes of reflow and was found to be much higher than in MAb R15.7-treated hearts, with a value similar to that of the HNRP group (Table) . Discussion Although early reperfusion of ischemic myocardium may limit ischemic injury, experimental evidence sug- Taken together, the results of this study provide strong evidence that anti-CD-18 therapy can prevent PMNmediated reperfusion injury and can markedly enhance the recovery of cardiac function following myocardial ischemia-reperfusion.
